meta
|
evidence
oncology
Living systematic review and meta-analysis
breast cancer - HER2-positive
All
A EFFACER all cancer
basal cell carcinoma
biliary tract cancer (BTC)
billiary tract cancer - (neo)adjuvant (NA)
billiary tract cancer - 1st line (L1)
billiary tract cancer - 2nd line (L2)
cholangiocarcinoma
breast cancer (BC)
breast cancer - adjuvant
breast cancer - HER2-positive
es-BC - HER2 negative - (neo)adjuvant (NA)
es-BC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive
la/mBC - HER2 positive - (neo)adjuvant (NA)
la/mBC - HER2 positive - 1st Line (L1)
la/mBC - HER2 positive - 2nd Line (L2)
breast cancer - HR positive
es-BC - HR positive - (neo)adjuvant (NA)
es-BC - HR-positive - 1st line (L1)
la/mBC - HR positive
la/mBC - HR positive - (neo)adjuvant (NA)
la/mBC - HR positive - NA - PIK3CA mutant
la/mBC - HR-positive - 1st line (L1)
la/mBC - HR positive - L1 - PIK3CA mutant
la/mBC - HR-positive - 2nd line (L2)
la/mBC - HR positive - L2 - all population
la/mBC - HR positive - L2 - PIK3CA mutant
breast cancer - triple negative
es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)
es-BC - TNBC - NA - all population
es-BC - TNBC - NA - PDL1 positive
es-BC - Triple negatif (TNBC) - 1st line (L1)
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)
mBC - Triple negative (TNBC) - 1st Line (L1)
mBC - TNBC - L1 - all population
mBC - TNBC - L1 - PDL1 positive
mBC-Triple negative (TNBC) - 2nd Line (L2)
mBC - TNBC - L2 - all population
mBC - TNBC - L2 - PDL1 positive
metastatic/advanced - breast cancer (mBC)
cervical cancer (CC)
classical Hodgkin lymphoma (cHL)
refractory classic Hodgkin lymphoma (R/R cHL)
R/R cHL - second line or more (L2)
colorectal cancer (CRC)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 1st line (L1)
mCRC - 2nd line (L2)
endometrial cancer
esophageal cancer (EC)
locally advanced - esophageal cancer (laEC)
laEC - Neo(adjuvant) (NA)
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
mEC - 1st line (L1)
mEC - 2nd line (L2)
gastric or gastroesophageal junction cancer (GC)
locally advanced (laGC)
laGC - (neo)adjuvant (NA)
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
mGC or mGEJC - L1 - HER2 negative
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
mGC or mGEJC - L2 - PDL1 positive
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
mGC or mGEJC - M - HER2 neg/PDL1 positive
gene alteration defined cancer
BRAF gene alteration defined cancer
BRCA1/2 gene alteration defined cancer
EGFR gene alteration defined cancer
EGFR exon 20 insertion mutation
FGFR (2/3) gene alteration defined cancer
KRAS gene alteration defined cancer
MET gene alteration defined cancer
NTRK gene alteration
RET gene alteration defined cancer
glioblastoma (GB)
metastatic glioblastoma (mGB) - 1st line (L1)
metastatic glioblastoma (mGB) - 2nd line (L2)
head and neck cancer squamous cell cancer (HNSCC)
locally advanced (laHNSCC)
laHNSCC - (neo)adjuvant (NA)
laHNSCC - 1st line (L1)
laHNSCC - 2nd line (L2)
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
mHNSCC - L1 - PDL1 positive
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
mHNSCC - L2 - PDL1 negative
mHNSCC - L2 - PDL1 positive
hepatocell cancer (HCC)
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
mHCC - 1st line (L1)
mHCC - 2nd line (L2)
lung cancer : non small cell (NSCLC)
early NSCLC - (neo)adjuvant (NA)
eNSCLC - NA - all population
eNSCLC - NA - EGFR mutant
early NSCLC - 1st line (L1)
locally advanced NSCLC - (neo)adjuvant (NA)
laNSCLC - NA - all population
locally advanced NSCLC - maintenance (M)
laNSCLC - M - all population
laNSCLC - M - EGFR mutant
metastatic/adv NSCLC (mNSCLC) - (neo)adjuvant (NA)
mNSCLC - NA - all population
metastatic/adv NSCLC (mNSCLC) - maintenance (M)
mNSCLC - M - all population
mNSCLC - M - EGFR mutant
mNSCLC - M - EGFR wild type
mNSCLC - M - PDL1 positive
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
mNSCLC - L1 - PDL1 positive
mNSCLC - L1 - TMB>10Mb
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
mNSCLC - L2 - PDL1 positive
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
squamous - mNSCLC - L2 - PDL1 positive
NSCLC adjuvant setting
NSCLC neoadjuvant setting
lung cancer : small cell (SCLC)
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
limited stage SCLC (ls-SCLC)
limited stage SCLC (ls-SCLC) - maintenance (M)
limited stage SCLC (ls-SCLC) - 2nd Line (L2)
melanoma (ML)
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
mML - NA - PDL1 positive
mML - 1st line (L1)
mML - L1 - all population
mML - L1 - BRAF mutant
mML - L1 - BRAF wild
mML - 2nd line (L2)
mML - L2 - all population
mML - L2 - BRAF mutant
mesothelioma (MS)
malignant mesothelioma (mMS) - (neo)adjuvant (NA)
malignant mesothelioma (mMS) - 1st line (L1)
malignant mesothelioma (mMS) - 2nd line (L2)
multiple myeloma
multiple myeloma - 1st line (L1)
multiple myeloma - 2nd line (L2)
myofibroblastic tumors
neurofibroma
neutropenia
osteosarcoma
ovarian cancer (OC)
metastatic/advanced OC (mOC) - (neo)adjuvant (NA)
metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - all population
mOC - L1 - PDL1 positive
metastatic/advanced OC (mOC) - 2nd line (L2)
metastatic/advanced OC (mOC) - maintenance (M)
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)
castration-resistant prostate cancer (CRPC)
metastatic (mCRPC) - 1st line (L1)
metastatic (mCRPC) - 2nd line (L2)
metastatic, hormone-sensitive prostate cancer
renal cell cancer (RCC)
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
metastatic/advanced RCC (mRCC) - 1st line (L1)
mRCC - L1 - PDL1 negative
mRCC - L1 - PDL1 positive
metastatic/advanced RCC (mRCC) - 2nd line (L2)
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
metastatic/advanced UC (mUC) - 1st Line (L1)
mUC - L1 - all population
mUC - L1 - PDL1 positive
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all population
mUC - L2 - PDL1 positive
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - all population
mUC - M - PDL1 positive
muscular invasive bladder cancer (MIBC)
MIBC - (neo)adjuvant (NA)
MIBC - NA - all population
MIBC - NA - PDL1 positive
non-muscle-invasive BC (NMIBC)
NMIBC - (neo)adjuvant (NA)
NMIBC - 1st line (L1)
NMIBC - 2nd line (L2)
antibody–drug conjugate
trastuzumab deruxtecan
trastuzumab emtansine
trastuzumab emtasine plus endocrine therapy
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib plus vinorelbine
HER2 inhibitor
neratinib based treatment
neratinib
neratinib plus capecitabine
pertuzumab based treatment
pertuzumab plus trastuzumab
pertuzumab plus trastuzumab plus docetaxel
trastuzumab based treatment
trastuzumab plus endocrine therapy
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
tucatinib based treatment
tucatinib plus trastuzumab plus capecitabine
TKI anti HER1/EGFR and HER2/neu
lapatinib based treatment
lapatinib
lapatinib plus capecitabine
lapatinib plus trastuzumab
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
inetetamab plus vinorelbine
target therapy
margetuximab based treatment
margetuximab plus chemotherapy
VEGF(R) inhibitor
bevacizumab based treatment
bevacizumab plus trastuzumab plus docetaxel
versus all
vs antibody–drug conjugate
vs trastuzumab emtansine
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs capecitabine
vs taxanes
vs paclitaxel
vs paclitaxel followed by doxorubicin plus cyclophosphamide
vs vinca alkaloids
vs vinorelbine
vs Standard of Care (SoC)
vs HER inhibitor
vs HER2 inhibitor
vs pertuzumab based treatment
vs pertuzumab plus trastuzumab plus cyclophosphamide
vs pertuzumab plus trastuzumab plus docetaxel
vs trastuzumab based treatment
vs trastuzumab
vs trastuzumab plus capecitabine
vs trastuzumab plus chemotherapy
vs trastuzumab plus docetaxel
vs trastuzumab plus endocrine therapy
vs trastuzumab plus vinorelbine
vs TKI anti HER1/EGFR and HER2/neu
vs lapatinib based treatment
vs lapatinib
vs lapatinib plus capecitabine
vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
vs non active control
vs placebo
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
table
graph
EGM
comparisons
color = results
color = ROB
demonstrated
suggested
inconclusive
safety concern
ongoing study
not assessable
low
moderate
serious
ongoing study
display ongoing
demontrated benefit only
breast cancer - HER2-positive
la/mBC - HER2 positive - 2nd Line (L2)
neratinib
ExteNET